1Glenmark's Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) is only approved for the indication(s) listed in Glenmark's approved label.

1 Glenmark's Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) is only approved for the indication(s) listed in Glenmark's approved label.

The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as ...

FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.

See USPI Dosing and Administration for specific details. In general, if IMFINZI requires interruption or discontinuation, administer systemic corticosteroid therapy (1 mg to 2 mg/kg/day prednisone or ...

Durvalumab plus gemcitabine and cisplatin significantly improved event free survival and overall survival compared with gemcitabine and cisplatin. The Food and Drug Administration (FDA) has ...

In general, if IMFINZI requires interruption or discontinuation, administer systemic corticosteroid therapy (1 mg to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less.

neoadjuvant chemotherapy alone AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical ...

The FDA has approved AstraZeneca’s Imfinzi (durvalumab) as the first and only perioperative immunotherapy for muscle-invasive bladder cancer (MIBC). The approval, granted under Priority Review status, ...